Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Table 1 Demographic and baseline characteristics (All PsA ixekizumab-exposure safety population)

Characteristics	All-IXE treatment periods(N = 1118)
Age, years, mean (SD)	49.5 (11.9)
Sex, n (%)
Male	517 (46.2)
Female	601 (53.8)
Race, n (%)
White	1056 (94.5)
Asian	39 (3.5)
American Indian or Alaska Native	9 (0.8)
Multiple	8 (0.7)
Black or African American	4 (0.4)
Native Hawaiian or other Pacific Islander	1 (0.1)
Weight, kg, mean (SD)	86.31 (20.4)
BMI, kg/m², mean (SD)	29.95 (6.9)
Previous PsA systemic therapy^a, n (%)
No prior treatment	218 (19.5)
Non-biologic only	562 (50.3)
Biologic only	71 (6.4)
Biologic and non-biologic	267 (23.9)
Duration of PsA symptoms in years, mean (SD)	9.71 (8.7)

All-IXE treatment period defined as all patients who received ≥ 1 dose of IXE
^aSystemic therapy includes biologic (such as anti-TNF inhibitors) and non-biologic (such as cDMARDs, NSAIDs, and corticosteroids) medications that were used prior to the study entry
bDMARDs biologic disease-modifying antirheumatic drugs, BMI body mass index, cDMARDs conventional disease-modifying antirheumatic drugs, IXE ixekizumab, N population size, n number in each group, NSAIDs non-steroidal anti-inflammatory drugs, PsA psoriatic arthritis, SD standard deviation

ISSN: 1478-6362